 The FDA has lifted the partial clinical hold on Kura Oncology Inc NASDAQ: KURA KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia AML. The partial clinical hold was lifted following an agreement with the agency on the companys mitigation strategy for differentiation syndrome, an adverse event related to differentiating agents in the treatment of AML. 